PMID- 25806711
OWN - NLM
STAT- MEDLINE
DCOM- 20150519
LR  - 20181113
IS  - 1537-453X (Electronic)
IS  - 0277-3732 (Print)
IS  - 0277-3732 (Linking)
VI  - 38
IP  - 2
DP  - 2015 Apr
TI  - MYC and human telomerase gene (TERC) copy number gain in early-stage non-small 
      cell lung cancer.
PG  - 152-8
LID - 10.1097/COC.0000000000000012 [doi]
AB  - OBJECTIVES: We investigated the frequency of MYC and TERC increased gene copy 
      number (GCN) in early-stage non-small cell lung cancer (NSCLC) and evaluated the 
      correlation of these genomic imbalances with clinicopathologic parameters and 
      outcome. MATERIALS AND METHODS: Tumor tissues were obtained from 113 resected 
      NSCLCs. MYC and TERC GCNs were tested by fluorescence in situ hybridization 
      (FISH) according to the University of Colorado Cancer Center (UCCC) criteria and 
      based on the receiver operating characteristic (ROC) classification. RESULTS: 
      When UCCC criteria were applied, 41 (36%) cases for MYC and 41 (36%) cases for 
      TERC were considered FISH-positive. MYC and TERC concurrent FISH-positive was 
      observed in 12 cases (11%): 2 (17%) cases with gene amplification and 10 (83%) 
      with high polysomy. By using the ROC analysis, high MYC (mean >/= 2.83 copies/cell) 
      and TERC (mean >/= 2.65 copies/cell) GCNs were observed in 60 (53.1%) cases and 58 
      (51.3%) cases, respectively. High TERC GCN was associated with squamous cell 
      carcinoma (SCC) histology (P=0.001). In univariate analysis, increased MYC GCN 
      was associated with shorter overall survival (P=0.032 [UCCC criteria] or P=0.02 
      [ROC classification]), whereas high TERC GCN showed no association. In 
      multivariate analysis including stage and age, high MYC GCN remained 
      significantly associated with worse overall survival using both the UCCC criteria 
      (P=0.02) and the ROC classification (P=0.008). CONCLUSIONS: Our results confirm 
      MYC as frequently amplified in early-stage NSCLC and increased MYC GCN as a 
      strong predictor of worse survival. Increased TERC GCN does not have prognostic 
      impact but has strong association with squamous histology.
FAU - Flacco, Antonella
AU  - Flacco A
AD  - *Department of Medical Oncology, S. Maria della Misericordia Hospital Departments 
      of daggerElectronic and Information Engineering double daggerThoracic Surgery  section signInstitute of 
      Pathological Anatomy and Histology, University of Perugia, Perugia, Italy 
       parallelDepartment of Medicine/Medical Oncology, University of Colorado Cancer Center, 
      Aurora, CO.
FAU - Ludovini, Vienna
AU  - Ludovini V
FAU - Bianconi, Fortunato
AU  - Bianconi F
FAU - Ragusa, Mark
AU  - Ragusa M
FAU - Bellezza, Guido
AU  - Bellezza G
FAU - Tofanetti, Francesca R
AU  - Tofanetti FR
FAU - Pistola, Lorenza
AU  - Pistola L
FAU - Siggillino, Annamaria
AU  - Siggillino A
FAU - Vannucci, Jacopo
AU  - Vannucci J
FAU - Cagini, Lucio
AU  - Cagini L
FAU - Sidoni, Angelo
AU  - Sidoni A
FAU - Puma, Francesco
AU  - Puma F
FAU - Varella-Garcia, Marileila
AU  - Varella-Garcia M
FAU - Crino, Lucio
AU  - Crino L
LA  - eng
GR  - P30 CA046934/CA/NCI NIH HHS/United States
GR  - P50 CA058187/CA/NCI NIH HHS/United States
GR  - P50 CA58187/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Clin Oncol
JT  - American journal of clinical oncology
JID - 8207754
RN  - 0 (telomerase RNA)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Area Under Curve
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/mortality/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - *Gene Dosage
MH  - Genes, myc/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*genetics/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Proportional Hazards Models
MH  - RNA/*genetics
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Telomerase/*genetics
PMC - PMC4607281
MID - NIHMS728705
EDAT- 2015/03/26 06:00
MHDA- 2015/05/20 06:00
PMCR- 2016/04/01
CRDT- 2015/03/26 06:00
PHST- 2015/03/26 06:00 [entrez]
PHST- 2015/03/26 06:00 [pubmed]
PHST- 2015/05/20 06:00 [medline]
PHST- 2016/04/01 00:00 [pmc-release]
AID - 00000421-201504000-00006 [pii]
AID - 10.1097/COC.0000000000000012 [doi]
PST - ppublish
SO  - Am J Clin Oncol. 2015 Apr;38(2):152-8. doi: 10.1097/COC.0000000000000012.